Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 15 (3), 259-64

Levorphanol: The Forgotten Opioid

Affiliations
Review

Levorphanol: The Forgotten Opioid

Eric Prommer. Support Care Cancer.

Abstract

Background: Levorphanol (levo-3-hydroxy-N-methylmorphinan) is a strong opioid that is the only available opioid agonist of the morphinan series. Levorphanol was originally synthesized as a pharmacological alternative to morphine more than 40 years ago. It is considered a step-3 opioid by the World Health Organization (WHO) and has a greater potency than morphine. Analgesia produced by levorphanol is mediated via its interactions with mu, delta, and kappa opioid receptors. Levorphanol is also an N-methyl-D-aspartate (NMDA) receptor antagonist. There is evidence that levorphanol may inhibit uptake of norepinephrine and serotonin. Similar to morphine, levorphanol undergoes glucuronidation in the liver, and the glucuronidated products are excreted in the kidney. Levorphanol can be given orally, intravenously, and subcutaneously.

Objective: This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this often overlooked step-3 opioid.

Conclusion: The long half-life of the drug increases the potential for drug accumulation. Levorphanol has clinical efficacy in neuropathic pain.

Similar articles

See all similar articles

Cited by 5 PubMed Central articles

References

    1. J Pharmacol Exp Ther. 1995 Sep;274(3):1263-70 - PubMed
    1. J Pain Symptom Manage. 1995 May;10(4):310-4 - PubMed
    1. J Pharmacol Exp Ther. 2003 Dec;307(3):1127-34 - PubMed
    1. Tumori. 1998 May-Jun;84(3):289-300 - PubMed
    1. J Pain Symptom Manage. 2005 May;29(5 Suppl):S90-103 - PubMed

MeSH terms

Feedback